why did fda stop tirzepatide crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many FDA says years-long tirzepatide shortage

The most common side effects of tirzepatide are related to the gastrointestinal tract and may include diarrhea, vomiting, constipation, decreased appetite, and bloating

GLP-1 receptor agonists: Similar to tirzepatide, these injectable weight loss drugs called GLP-1 inhibitors have been found to be highly effective in lowering blood sugar levels by increasing insulin production and decreasing glucagon release from the pancreas

In: Marriott B.M., editor

Among those subjects, roughly 3,000 had been prescribed semaglutide, which is also the active ingredient in Novos weight loss pill Rybelsus

Clinical Evidence on GLP-1 Drugs and Sweet Food Preference Multiple randomized controlled trials show that GLP-1 receptor agonists significantly reduce preference for high-sugar and high-fat foods